BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1293176)

  • 1. Nosological considerations of the neurofibromatoses.
    Viskochil D; Carey JC
    J Dermatol; 1992 Nov; 19(11):873-80. PubMed ID: 1293176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromatosis. Nosological considerations.
    Badiu C; Stefanache F
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(2):39-44. PubMed ID: 12089989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurofibromatoses. Types, classification and diagnostic criteria].
    Poptodorov G
    Khirurgiia (Sofiia); 2001; 57(1-2):56-8. PubMed ID: 12024659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The different forms of neurofibromatosis.
    Ruggieri M
    Childs Nerv Syst; 1999 Jul; 15(6-7):295-308. PubMed ID: 10461778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
    Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
    J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
    Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
    Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurofibromatosis].
    Wolkenstein P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostics of neurofibromatosis (Recklinghausen disease)].
    Ardashev VN; Seriakov AP; Nikolaeva SN; Konev AV; Smolin AV
    Voen Med Zh; 2004 Jun; 325(6):41-4. PubMed ID: 15327140
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
    Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
    Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous Detection of
    Bianchessi D; Ibba MC; Saletti V; Blasa S; Langella T; Paterra R; Cagnoli GA; Melloni G; Scuvera G; Natacci F; Cesaretti C; Finocchiaro G; Eoli M
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32575496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the neurofibromatoses.
    Gutmann DH
    Curr Opin Neurol; 1994 Apr; 7(2):166-71. PubMed ID: 8019663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple or familial cafĂ©-au-lait spots is neurofibromatosis type 6: clarification of a diagnosis.
    Madson JG
    Dermatol Online J; 2012 May; 18(5):4. PubMed ID: 22630574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurofibromatoses. An overview.
    Ruggieri M; Huson SM
    Ital J Neurol Sci; 1999 Apr; 20(2):89-108. PubMed ID: 10933430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurofibromatoses].
    Zimmer A
    Radiologe; 2013 Dec; 53(12):1077-83. PubMed ID: 24258315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterization of neurofibromatosis in southern Brazil.
    Rosset C; Vairo F; Cristina Bandeira I; Fonini M; Netto CBO; Ashton-Prolla P
    Expert Rev Mol Diagn; 2018 Jun; 18(6):577-586. PubMed ID: 29685074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Importance of multidisciplinary consultations for children with neurofibromatosis].
    Bursztyn J; Rodriguez D
    J Fr Ophtalmol; 1999 Nov; 22(9):959-62. PubMed ID: 10609170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.